Comparative Pharmacology
Head-to-head clinical analysis: MEPSEVII versus SPRX 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEPSEVII versus SPRX 3.
MEPSEVII vs SPRX-3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MEPSEVII (vestronidase alfa) is a recombinant form of human beta-glucuronidase that hydrolyzes accumulated glycosaminoglycans (GAGs) in lysosomes, restoring enzymatic activity in patients with Mucopolysaccharidosis VII (Sly syndrome).
Selective sigma-2 receptor ligand; induces mitochondrial dysfunction and endoplasmic reticulum stress leading to apoptosis in cancer cells. Also modulates autophagy.
1 mg/kg administered intravenously once weekly over 4 hours.
Not established; investigational drug. No approved standard adult dose available.
None Documented
None Documented
Terminal elimination half-life: 9.4 hours (range 6.3–16.6 hours) in patients with mucopolysaccharidosis VII; supports weekly intravenous dosing.
Terminal elimination half-life: 12 ± 3 hours; requires dose adjustment in renal impairment (CrCl <30 mL/min).
Renal: negligible; primarily catabolized via peptide hydrolysis to amino acids, which are recycled or excreted in urine as metabolites.
Primarily renal (70% unchanged, 15% as glucuronide conjugate); biliary/fecal (10%); other (5%).
Category C
Category C
Unknown
Unknown